Short Interest in PDS Biotechnology Co. (NASDAQ:PDSB) Increases By 20.7%

PDS Biotechnology Co. (NASDAQ:PDSB - Get Free Report) was the recipient of a significant increase in short interest in February. As of February 28th, there was short interest totalling 4,670,000 shares, an increase of 20.7% from the February 13th total of 3,870,000 shares. Currently, 13.8% of the company's stock are short sold. Based on an average daily volume of 630,100 shares, the short-interest ratio is presently 7.4 days.

Analysts Set New Price Targets

A number of equities analysts recently commented on PDSB shares. HC Wainwright reiterated a "buy" rating and set a $21.00 target price on shares of PDS Biotechnology in a research note on Thursday, March 13th. B. Riley lowered their target price on shares of PDS Biotechnology from $9.00 to $7.00 and set a "buy" rating for the company in a research note on Monday, November 25th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $11.67.

Hedge Funds Weigh In On PDS Biotechnology

Several large investors have recently bought and sold shares of PDSB. Renaissance Technologies LLC boosted its stake in PDS Biotechnology by 331.0% in the fourth quarter. Renaissance Technologies LLC now owns 100,000 shares of the company's stock valued at $163,000 after acquiring an additional 76,800 shares in the last quarter. Virtu Financial LLC acquired a new position in PDS Biotechnology in the fourth quarter valued at $89,000. Two Sigma Investments LP boosted its stake in shares of PDS Biotechnology by 273.5% during the fourth quarter. Two Sigma Investments LP now owns 65,732 shares of the company's stock worth $107,000 after buying an additional 48,132 shares during the period. XTX Topco Ltd boosted its stake in shares of PDS Biotechnology by 241.8% during the third quarter. XTX Topco Ltd now owns 67,182 shares of the company's stock worth $257,000 after buying an additional 47,528 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of PDS Biotechnology by 9.8% during the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company's stock worth $1,586,000 after buying an additional 37,142 shares during the period. Institutional investors and hedge funds own 26.84% of the company's stock.

Remove Ads

PDS Biotechnology Stock Performance

NASDAQ PDSB traded up $0.01 during trading hours on Friday, hitting $1.37. The company had a trading volume of 172,720 shares, compared to its average volume of 565,103. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. PDS Biotechnology has a 1-year low of $1.13 and a 1-year high of $4.92. The company has a market cap of $52.32 million, a PE ratio of -1.18 and a beta of 1.68. The business has a 50 day moving average of $1.42 and a 200-day moving average of $2.22.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.